Drugs / Latanoprost
Latanoprost
also known as
Xalatan · PhXA41 · T-2345 · Monoprost · Catioprost · D565H · GAAP Ofteno · GALAXIA · +11 more
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Roclanda | — | 2021-01-07 | europa.eu ↗ |
| Label expansion | US (FDA) | XALATAN | — | 2002-12-20 | fda.gov ↗ |
| Approved | US (FDA) | XALATAN | — | 1996-06-05 | fda.gov ↗ |
Trials 109 · started per year
today
US approved 1996
EU approved 2021
2
1
1
1
2
1
5
1
10
5
5
5
10
7
5
3
6
7
4
1
4
2
2
5
2
1
2
2
3
2
1992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06730516 | Jun → Sep 2024 | glaucoma | Zagazig University | Completed | No outcome recorded |
| Phase 0 | NCT05790941 | Mar → Jun 2023 | hypotrichosis | Aneira Pharma, Inc. | Unknown | No outcome recorded |
| Phase 0 | NCT04234932 | Jan 2020 → Jan 2021 | open-angle glaucoma | University of the Incarnate Word | Unknown | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT06629129 | Jun → Aug 2024 | — | Zagazig University | Completed | No outcome recorded |
| Phase 1 | NCT04060758 | Mar 2020 → May 2025 | open-angle glaucoma | PolyActiva Pty Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03293992 | Oct → Dec 2017 | ocular hypertension, open-angle glaucoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02622334 | Dec 2015 → Jul 2016 | glaucoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00638742 | May 2008 → Mar 2009 | glaucoma, ocular hypertension | Viatris Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02129673 | May 2014 → May 2017 | ocular hypertension, open-angle glaucoma | ViSci Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT01987323 | Jan → Jun 2013 | ocular hypertension | Singapore Eye Research Institute | Completed | No outcome recorded |
| Phase 232 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT07016113 | Jul → Oct 2025 overdue | vitiligo | Padjadjaran University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06964191 | May 2025 → Nov 2026 expected | ocular hypertension, open-angle glaucoma | PolyActiva Pty Ltd | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04448223 | Jun 2020 → Dec 2022 | ocular hypertension, open-angle glaucoma | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 2 | NCT04205201 | Jun 2018 → Sep 2019 | — | Chittagong Medical College | Completed | No outcome recorded |
| Phase 2 | NCT03067415 | Mar → Sep 2017 | ocular hypertension, open-angle glaucoma | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 2 | NCT03292796 | Dec 2016 → Oct 2019 | open-angle glaucoma | Julie Dawson | Completed | No outcome recorded |
| Phase 2 | NCT02057575 | Jan → Jun 2014 | ocular hypertension, open-angle glaucoma | Aerie Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT02014142 | Dec 2013 → Dec 2016 | ocular hypertension, open-angle glaucoma | Mati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01973114 | Oct 2013 → May 2016 | Meniere disease | Synphora AB | Unknown | No outcome recorded |
| Phase 2 | NCT01481077 | Nov 2011 → Sep 2012 | glaucoma, ocular hypertension | Mati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01481051 | Nov 2011 → Sep 2012 | glaucoma, ocular hypertension | Mati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01426464 | Sep → Nov 2011 | glaucoma | Nanduri, Padma, M.D., FACS | Unknown | No outcome recorded |
| Phase 2 | NCT01254370 | Nov 2010 → Jun 2011 | eye adnexa disorder, glaucoma, ocular hypertension | Santen SAS | Completed | No outcome recorded |
| Phase 2 | NCT01229982 | Oct 2010 → Aug 2011 | ocular hypertension, open-angle glaucoma | Mati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01060579 | Feb → Aug 2010 | glaucoma | Aerie Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00934089 | Jan → Jun 2010 | ocular hypertension, open-angle glaucoma | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01037036 | Dec 2009 → Apr 2010 | ocular hypertension, open-angle glaucoma | Mati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00967811 | Aug 2009 → May 2010 | glaucoma, ocular hypertension | Mati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01527682 | Jul 2009 → Nov 2016 | congenital glaucoma | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Completed | No outcome recorded |
| Phase 2 | NCT00855517 | Mar → Jul 2009 | glaucoma, ocular hypertension | Mati Therapeutics Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT00821002 | Jan → Nov 2009 | ocular hypertension, open-angle glaucoma | Mati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00820300 | Jan → Dec 2009 | glaucoma, ocular hypertension | Mati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00845299 | Jan → Dec 2009 | glaucoma, ocular hypertension | Mati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01494753 | Jun → Dec 2008 | open-angle glaucoma | Laboratoires Thea | Completed | No outcome recorded |
| Phase 2 | NCT00650702 | Mar 2008 → Feb 2009 | glaucoma, ocular hypertension | Mati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00572455 | Dec 2007 → Jun 2009 | ocular hypertension, open-angle glaucoma | Pfizer | Completed | Mixed |
| Phase 2 | NCT00595101 | Dec 2007 → Jun 2008 | ocular hypertension, open-angle glaucoma | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT00465621 | Mar → Jul 2007 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT00572936 | Mar 2006 → Nov 2009 | glaucoma | University of Nebraska | Completed | No outcome recorded |
| Phase 2 | NCT00579969 | Dec 2003 → Oct 2008 | glaucoma | University of Nebraska | Terminated | No outcome recorded |
| Phase 2 | NCT01379144 | Jan → Mar 2003 | ocular hypertension, open-angle glaucoma | Viatris Inc. | Completed | Missed primary |
| Phase 2 | NCT00143429 | — | ocular hypertension, open-angle glaucoma | Viatris Inc. | Withdrawn | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06960629 | May 2025 → Apr 2026 | bullous keratopathy, glaucoma | University Hospital Dubrava | Completed | No outcome recorded |
| Phase 325 trials · 3 met primary · 1 missed | ||||||
| Phase 3 | NCT07435012 | Apr 2026 → Dec 2027 expected | androgenetic alopecia | Triple Hair Inc | Recruiting | No outcome recorded |
| Phase 3 | NCT04133311 | Apr 2019 → Feb 2022 | eye adnexa disorder, open-angle glaucoma | Santen SAS | Completed | No outcome recorded |
| Phase 3 | NCT03284853 | Sep 2017 → Nov 2020 | ocular hypertension, open-angle glaucoma | Aerie Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02801617 | Sep 2015 → Mar 2017 | ocular hypertension, open-angle glaucoma | Laboratorios Sophia S.A de C.V. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02390284 | Sep 2015 → Oct 2024 | glaucoma | University of Miami | Terminated | No outcome recorded |
| Phase 3 | NCT02059278 | Jan 2014 → Jan 2015 | ocular hypertension, open-angle glaucoma | Nephron Pharmaceuticals Corporation | Completed | Met primary |
| Phase 3 | NCT01721707 | Dec 2012 → Mar 2013 | ocular hypertension, open-angle glaucoma | Adapt Produtos Oftalmológicos Ltda. | Withdrawn | No outcome recorded |
| Phase 3 | NCT00912054 | Mar 2010 → May 2011 | ocular hypertension, open-angle glaucoma | Alcon Research | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01156012 | Sep 2009 → Dec 2010 | glaucoma | Laboratoires Thea | Completed | No outcome recorded |
| Phase 3 | NCT00716859 | Jul 2008 → Nov 2009 | glaucoma | Viatris Inc. | Completed | Missed primary |
| Phase 3 | NCT00383019 | Nov 2006 → Oct 2007 | glaucoma, ocular hypertension | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00546286 | May 2006 → Aug 2007 | ocular hypertension, open-angle glaucoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00277498 | Dec 2005 → Jun 2007 | ocular hypertension, open-angle glaucoma | Viatris Inc. | Completed | Mixed |
| Phase 3 | NCT00230763 | Sep 2005 → Oct 2007 | ocular hypertension, open-angle glaucoma | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00159653 | Jul 2005 → Jun 2007 | ocular hypertension, open-angle glaucoma | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00219596 | Jun 2005 → Sep 2006 | ocular hypertension, open-angle glaucoma | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00051142 | Feb 2001 → Jun 2004 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00051155 | Jan 2001 → Jul 2004 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00051181 | Jan 2000 → Jun 2003 | chronic closed-angle glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00800267 | Jul 1997 → Jun 1999 | glaucoma, ocular hypertension | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00751127 | Jan 1993 → Feb 1994 | ocular hypertension, open-angle glaucoma | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00751049 | Dec 1992 → Dec 1993 | ocular hypertension, open-angle glaucoma | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00751062 | Nov 1992 → Dec 1993 | ocular hypertension, open-angle glaucoma | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02154217 | ? → Dec 2004 | glaucoma | University of Milan | Completed | Met primary |
| Phase 3 | NCT00283764 | — | ocular hypertension, open-angle glaucoma | Viatris Inc. | Withdrawn | No outcome recorded |
| Phase 430 trials | ||||||
| Phase 4 | NCT04401982 | Jul 2026 → Mar 2027 expected | borderline glaucoma, ocular hypertension | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 4 | NCT05606796 | Dec 2022 → Aug 2023 | — | Uzoma Chinyei Joan | Unknown | No outcome recorded |
| Phase 4 | NCT04702789 | Oct 2021 → Nov 2023 | ocular hypertension, open-angle glaucoma | Laboratorios Sophia S.A de C.V. | Terminated | No outcome recorded |
| Phase 4 | NCT04412096 | Nov 2020 → May 2025 | glaucoma, ocular hypertension | Ohio State University | Completed | No outcome recorded |
| Phase 4 | NCT04098861 | Jan 2019 → Aug 2020 | open-angle glaucoma | Universiti Kebangsaan Malaysia Medical Centre | Unknown | No outcome recorded |
| Phase 4 | NCT03331770 | Jan → Oct 2017 | open-angle glaucoma | Laboratorios Poen | Completed | No outcome recorded |
| Phase 4 | NCT02792803 | Sep 2015 → Apr 2017 | ocular hypertension, open-angle glaucoma | Dr. David Yan | Unknown | No outcome recorded |
| Phase 4 | NCT01927406 | Jun 2014 → Dec 2016 | endocrine exophthalmos, glaucoma, ocular hypertension | Stanford University | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT03966560 | Jan 2014 → Jan 2015 | open-angle glaucoma | Afyon Kocatepe University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02047630 | Jan → Dec 2014 | ocular hypertension, open-angle glaucoma | CHU de Quebec-Universite Laval | Terminated | No outcome recorded |
| Phase 4 | NCT02017327 | Dec 2013 → Jul 2016 | ocular hypertension, open-angle glaucoma | Laboratoires Thea | Completed | No outcome recorded |
| Phase 4 | NCT01975714 | Oct 2013 → Feb 2015 | glaucoma, ocular hypertension | Association for Innovation and Biomedical Research on Light and Image | Completed | No outcome recorded |
| Phase 4 | NCT01677507 | Aug 2012 → Aug 2016 | glaucoma | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT01535768 | Feb 2012 → Jun 2018 | glaucoma | Credit Valley EyeCare | Unknown | No outcome recorded |
| Phase 4 | NCT01978015 | Oct 2011 → Jul 2012 | anterior uveitis, cystoid macular edema | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 4 | NCT01225653 | Nov 2010 → Dec 2014 | diabetic retinopathy | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT00941525 | Sep 2009 → Jul 2014 | ocular hypertension, open-angle glaucoma | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| Phase 4 | NCT00798694 | Nov 2008 → Jan 2011 | glaucoma | Wills Eye | Completed | No outcome recorded |
| Phase 4 | NCT00468988 | May → Jul 2007 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00397241 | Sep 2006 → Dec 2007 | open-angle glaucoma | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| Phase 4 | NCT00329095 | Dec 2005 → Apr 2006 | glaucoma, ocular hypertension | Robin, Alan L., M.D. | Completed | No outcome recorded |
| Phase 4 | NCT00273481 | Sep 2005 → Apr 2007 | ocular hypertension, open-angle glaucoma | Pharmaceutical Research Network | Completed | No outcome recorded |
| Phase 4 | NCT00140049 | Jul 2005 → Jul 2006 | ocular hypertension, open-angle glaucoma | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00304785 | May 2005 → Oct 2007 | ocular hypertension, open-angle glaucoma | Pharmaceutical Research Network | Completed | No outcome recorded |
| Phase 4 | NCT00273429 | Apr → Dec 2005 | ocular hypertension, open-angle glaucoma | Pharmaceutical Research Network | Completed | No outcome recorded |
| Phase 4 | NCT00224289 | Mar 2005 → Apr 2009 | glaucoma | Yale University | Completed | No outcome recorded |
| Phase 4 | NCT00647101 | Dec 2003 → Feb 2005 | ocular hypertension, open-angle glaucoma | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00308945 | Nov 2003 → Feb 2005 | open-angle glaucoma | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT00143208 | May 2003 → Apr 2006 | glaucoma, ocular hypertension | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00140062 | Feb 2002 → Apr 2006 | ocular hypertension, open-angle glaucoma | Pfizer | Completed | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT05850936 | Jun 2023 → Nov 2026 expected | myopia | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| — | NCT04891588 | Mar → Sep 2021 | ocular hypertension, open-angle glaucoma | University Hospital Centre Zagreb | Unknown | No outcome recorded |
| — | NCT04296916 | Apr 2020 → Oct 2024 | borderline glaucoma, myopia | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT04737928 | Apr 2018 → Jan 2019 | open-angle glaucoma | Santen Pharmaceutical (Taiwan) Co., LTD | Completed | No outcome recorded |
| — | NCT02522039 | May → Nov 2014 | glaucoma | Glostrup University Hospital, Copenhagen | Completed | No outcome recorded |
| — | NCT02656979 | Dec 2013 → Sep 2019 | glaucoma | Umeå University | Unknown | No outcome recorded |
| — | NCT01430923 | Sep 2011 → May 2012 | ocular hypertension, open-angle glaucoma | Aurolab | Unknown | No outcome recorded |
| — | NCT01084902 | Feb → Sep 2010 | ocular hypertension | Peking University First Hospital | Unknown | No outcome recorded |
| — | NCT01361841 | Jan 2009 → Jan 2012 | ocular hypertension, open-angle glaucoma | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Unknown | No outcome recorded |
| — | NCT00619034 | Sep 2007 → Dec 2010 | diabetic retinopathy | University of Aarhus | Completed | No outcome recorded |
| — | NCT00440336 | Oct 2006 → ? | open-angle glaucoma | Advanced Glaucoma Specialists | Unknown | No outcome recorded |
| Comparator or background therapy116 trials | ||||||
| Phase 0 | NCT07425535 Background | Jun 2026 → Mar 2028 expected | glaucoma | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT04500574 Comparator | Apr 2024 → Oct 2025 | glaucoma, ocular hypertension | Massachusetts Eye and Ear Infirmary | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02531152 Comparator | Sep 2015 → Apr 2016 | open-angle glaucoma | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02108288 Comparator | Apr → May 2014 | glaucoma, ocular hypertension | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01180062 Comparator | Jan 2011 → Jun 2014 | ocular hypertension, open-angle glaucoma | Daniel Moore | Terminated | No outcome recorded |
| Show all 116 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2024-12-11 | Santen Gmbh | Regulatory Santen New Drug Application Filing Accepted for Review in South Korea and Vietnam for the Use of STN1013001 (Cationic Emulsion of Latanoprost 50μg/mL) in Glaucoma santen.com ↗ |
| 2024-10-30 | PolyActiva Pty Ltd | Results PolyActiva showcases repeat-dose clinical data out to 48 weeks polyactiva.com ↗
The trial met its efficacy and safety endpoints, representing a significant step forward in the company's vision to provide long-term, reliable drug delivery for glaucoma patients. |
| 2023-11-17 | Santen Gmbh | Regulatory Santen Receives European Commission Approval for Catiolanze® (cationic emulsion of latanoprost 50μg/mL) for Lowering of Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension santen.com ↗
Santen Pharmaceutical Co., Ltd. (hereinafter, Santen) announced the European Commission (EC) has approved the Marketing Authorization Application (MAA) for Catiolanze® (cationic emulsion of latanoprost 50μg/mL, STN1013001) for lowering of intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. |
| 2022-10-06 | Santen Gmbh | Regulatory Santen filing accepted by European Medicines Agency (EMA) for review of application for marketing authorization of the use of STN1013001 cationic emulsion of latanoprost 50?g/mL in glaucoma santen.com ↗
Santen Pharmaceutical Co ., Ltd . (Head Office : Osaka; hereinafter “Santen”) announced the European Medicines Agency (EMA) has accepted for review the marketing authorization application for the use of STN1013001 for lowering of intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. |
| 2022-04-11 | NicOx Inc. | Results Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma nicox.com ↗
All tested concentrations of NCX 470 were statistically non-inferior to latanoprost and the dose response of NCX 470 showed improved IOP lowering with each incremental concentration. |
| 2022-03-17 | PolyActiva Pty Ltd | Results PolyActiva presents positive clinical trial results polyactiva.com ↗
The open-label, multicenter, Phase IIa study met both its primary and secondary efficacy endpoints of at least 20% IOP lowering in its low dose cohort |
| 2016-09-28 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Regulatory Otsuka Receives Approval in Japan for Mikeluna Combination Ophthalmic Solution, a New Treatment for Glaucoma and Ocular Hypertension® otsuka.co.jp ↗
Otsuka Pharmaceutical Co., Ltd. on September 28, 2016 obtained regulatory approval in Japan for the manufacture and marketing of Mikeluna combination ophthalmic solution for glaucoma and intraocular hypertension. |
| 2015-10-01 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Regulatory New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension otsuka.co.jp ↗
Otsuka Pharmaceutical Co., Ltd., announced that it has submitted a new drug application to the Japanese Ministry of Health, Labour and Welfare for regulatory approval of, carteolol hydrochloride/ latanoprost, a novel combined ophthalmic solution. |
All press releases naming this drug 11 releases
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 228 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Latanoprost | “To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure...” NCT00159653 ↗213“a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs...” NCT01535768 ↗ “prostaglandin analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one - randomised eye.” NCT01927406 ↗ “TH07 is a combined topical spray solution containing three active ingredients commonly used to treat hair loss: Minoxidil (5%) Finasteride (0.1%) and Latanoprost (0.03%).” NCT07435012 ↗ “Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days).” NCT04702789 ↗ “PURPOSE: To assess ocular surface changes in participants using latanoprost with benzalkonium chloride (Xalatan) and travoprost with SofZia (Travatan Z).” PMID 28617732 ↗ Nov 2018 “This study is designed as an open label evaluation of the efficacy of latanoprost and timolol fixed combination (Xalacom) after 6 month of treatment.” NCT00143208 ↗ “A 6-month, Randomized, Double-masked Comparison of Latanoprost (PhXA41) With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension.” NCT00751127 ↗ “OBJECTIVE: To assess the efficacy and safety of fixed-combination latanoprost-timolol (FCLT) vs latanoprost or timolol monotherapy.” PMID 20142538 ↗ Feb 2010 “IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the choice for treatment.” NCT05850936 ↗ “Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use.” NCT02017327 ↗ |
| Known as | Catioprost | “Catioprost® (Unpreserved Latanoprost 0.005% Emulsion)” NCT01254370 ↗ |
| Known as | D565H | “D565H(Latanoprost 25㎍/㎖)” NCT03067415 ↗ |
| Known as | GAAP Ofteno | “known formulation of Latanoprost 0.005% (GAAP Ofteno®, Laboratorios Sophia, Mexico)” NCT02801617 ↗ |
| Known as | GALAXIA | “patients will receive in each eligible eye one drop of GALAXIA© Latanoprost eyedrops once a day, in the evening (8pm), for two months” NCT01580254 ↗ |
| Known as | IOPIZE | “patients will receive in each eligible eye one drop of IOPIZE© Latanoprost eyedrops once a day, in the evening (8pm), for two months” NCT01580254 ↗ |
| Known as | LAT | “Commercially available, FDA-approved generic latanoprost ophthalmic solution, 0.005% (LAT) without modification will be used as the active control” NCT05165290 ↗ |
| Known as | Latanoprost (Xalatan) | “Latanoprost (Xalatan)” NCT00187577 ↗ |
| Known as | Latanoprost RATIOPHARM | “patients will receive in each eligible eye one drop of Latanoprost RATIOPHARM© Latanoprost eyedrops once a day, in the evening (8pm), for two months” NCT01580254 ↗ |
| Known as | Latanoprost T | “Three of these are commonly used in North America: latanoprost (Latanoprost T, Pfizer), Travoprost (Travatan TM, Alcon) and bimatoprost (Lumigan TM, Allergan).” NCT01361841 ↗ |
| Known as | latanprost | “Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.” NCT00690794 ↗ |
| Known as | LUDPF | “Preservative-free latanoprost 0.005% Unit Dose (LUDPF) (Monoprost) eye drops will be administered every day at 21:00 for the first 3 months.” NCT01975714 ↗ |
| Known as | Monoprost | “Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use.” NCT02017327 ↗1“Monoprost (preservative-free latanoprost eye drop)” NCT04743622 ↗ |
| Known as | PA5108 | “PA5108 (PolyActiva product code) Latanoprost free acid (FA) sustained release (SR) Ocular Implant” NCT04060758 ↗ |
| Known as | PhXA41 | “A 6-month, Randomized, Double-masked Comparison of Latanoprost (PhXA41) With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension.” NCT00751127 ↗ |
| Known as | POLAT-001 | “Subconjunctival liposomal Latanoprost (POLAT-001)” NCT02466399 ↗ |
| Known as | T-2345 | “T-2345 nonpreserved ophthalmic solution (latanoprost 0.005%)” NCT02059278 ↗ |
| Known as | Xalatan | “A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary...” PMID 22607109 ↗ May 201227“Researchers want to find out more about how 2 drugs called Cosopt (dorzolamide hydrochloride and timolol maleate) and Xalatan (latanoprost) can help people with these conditions.” NCT00440336 ↗ “XALATAN® (latanoprost ophthalmic solution) is an eye drop used to treat high eye pressure/intraocular pressure in people with open-angle glaucoma or ocular hypertension.” NCT03318146 ↗ “Latanoprost (Xalatan\*) is a prostaglandin F2\* analogue which is believed to reduce IOP by increasing the outflow of aqueous humor.” NCT00815373 ↗ “dosed with TRAVATAN Z®, XALATAN®, or LUMIGAN®, 1 drop instilled in each eye once daily for 28 days” NCT01937312 ↗ “Latanoprost (Xalatan) ophthalmic solution compared to bimatoprost (Lumigan) ophthalmic solution” NCT00187577 ↗ “Latanoprost( xalatan 0.005% ) is applied to the treated area for all participants.” NCT06239324 ↗ “Xalatan/latanoprost 0.005% ophthalmic solution one drop qhs for one year” NCT00705757 ↗ “carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)” NCT00972426 ↗ “Latanoprost 0.005% ophthalmic solution (Xalatan)” NCT00759941 ↗ “Latanoprost 0.005% Ophthalmic Solution (XALATAN)” NCT00293800 ↗ |
| Known as | XALATAN (Latanoprost ophthalmic solution, 0.005%) | “XALATAN® (Latanoprost ophthalmic solution, 0.005%)” NCT02419508 ↗ |
| Known as | XalatanTM | “All patients treated with topical Latanoprost 0.005% (XalatanTM, 2.5 ml eye drops, Pfizer)” NCT06629129 ↗ |
| Action | Activate | “the FP agonist Xalatan” PMID 27649982 ↗ Sep 2016 |
| Modality | Small molecule | “Latanoprost is a synthetic prodrug of 17-phenyl-substituted prostaglandin F2α analog.” NCT00712400 ↗ |
| Route | Topical | “Subject will apply latanoprost to affected eyelid with cotton-tipped applicator daily.” NCT00187577 ↗ |